We restore endothelial cell function

About Pantherna

Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.

Our Science

Latest News

PRESS RELEASE
11 January, 2022
Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs  

Hennigsdorf, January 11, 2022 – Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).   

FULL TEXT (ENG)
FULL TEXT (DE)
All News

Our Team

Pantherna Team

Our Locations

Headquarters

Pantherna Therapeutics GmbH
Innovationsforum Hennigsdorf

Neuendorfstrasse 20b
D-16761 Hennigsdorf
Germany

R&D Site

Pantherna Therapeutics GmbH
Bayer AG CoLaborator Berlin

Müllerstraße 178
D-13353 Berlin
Germany

How can we help?

Please note our Privacy Policy